We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fastforward Innovations Limited | LSE:FFWD | London | Ordinary Share | GG00BRK9BQ81 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.25 | 8.00 | 8.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/3/2021 14:18 | This is the cannabis stock to be in ANA - will be producing 200 TONS !!! 50% shares held by 4 people 30% by BOD £6m mkt cap Share price 1.1p | gordan ghetto | |
04/3/2021 14:00 | News about Juvenesence Two of @juvlabs investee companies, AgeX Therapeutics and LyGenesis, have announced that they are in the process of negotiating an agreement for the merger of the two companies, combining their pipeline human aging and cell therapies - read more: hxxp://bwnews.pr/2Ok There is a lot of activity in the FFWD portfolio. | 888icb | |
04/3/2021 13:55 | News from Portage today Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited (PPL), including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd., a company developing therapies to transform the way people age. This asset disposition reflects a continuum of Portage's business strategy to focus on its pipeline of immuno-oncology platforms. In exchange for the assets, the out-licensing agreement states that Portage may be entitled to receive up to USD $244 million in future milestone payments based on specified development criteria. The Company will also be eligible to receive royalties in the future on global net sales of products developed utilizing the PPL intellectual property. | 888icb | |
04/3/2021 13:09 | I’ve held on and off for over 4 years. After a couple of years realised it was better to try and trade a portion of my holding and keep some long term. Made a decent 50% in a matter of weeks just this last month . Back in my trading account at 11. Don’t see any mega gains until Leap and Emmac. | mellonsbellend | |
04/3/2021 13:04 | It will be disappointing if your 50% doesn’t come in weeks rather than months! We have all become somewhat jaded waiting for liquidity events from FFWD but finally it seems we are about to be rewarded. | 888icb | |
04/3/2021 12:44 | Totally agree. Emmac ASAP While markets are hot. ( being sarcastic regarding raises 888 ) they have diluted FFWD enough over the years. I’ve topped up my trading account at 11p. Was hoping to get cheaper but expect I could get another 50% from this buy sometime in the next few months. | mellonsbellend | |
04/3/2021 12:40 | Ed made it clear they were not intending to have any further raises this year, when asked is it likely to be necessary to raise more funds in 2021.He said “We believe we are in a great cash position and we have a number of liquidity events so there is no reason on the horizon that will require a capital raise” My impression is that the EMMAC liquidity event could happen at any moment. The current activity in the cannabis space is such at the moment and the valuations so high that it would be bordering on negligence not to take advantage. They came very close last year with a spac so should be able to move quickly. I very much hope the traders miss the large rise that will happen when that is announced at which point they will have to pay a lot more than 12p to get in prior to the Leap liquidity event. | 888icb | |
04/3/2021 11:25 | I think most have heard the likes of this all before yogaboy. They already raised their MCAP by over £4m over the last few months with their diluting raises... Keep doing that and they might get close. I really don’t think it will get anywhere near there until Leap gives us that. Until then those without the patience will sell. I’ve recently bought a chunk at 8 and sold at 14 and maybe ready to buy a bit more soon. It’s not cheap but I do believe another 50% is possible over a couple of months if bought around 10p. | mellonsbellend | |
04/3/2021 11:20 | First target for market cap is 50 million, then somehow it will leap to 100 million by the end of the year.Sorry was that too subtle? | yogaboy | |
04/3/2021 10:19 | I know Ed had a lot of others asking why he hasn’t bought yet. Like he stated there was opportunity to buy in but he wanted to wait until he could buy a decent amount and not just £10k worth at a time..... ( so he had a chance to buy and didn’t ....but will buy in the future ....when hopefully the price is higher ...lol ) he bought a few tranches of his other company in £10k lots. I’ve held on and off for years and still hold a decent amount after cashing in a 50% gain here in just a couple of months but even at this price drop I don’t think it’s cheap. It’s 11.5 to buy now. I might top up more in the 10s. | mellonsbellend | |
04/3/2021 09:56 | Well Leap was valued independently last year to come up with the last valuation. Since then they have advanced again with huge progress. We did find out that they are not profitable yet for Q4 2020. as they had previously stated they would be profitable by then . I’m pleased they also picked up on expenses. A lot of people asking questions about that. Those who held over 4 years back will remember the days of costs exceeding 12% of NAV each year which was ridiculous. It’s around 7% now and they are saying it will reduce. | mellonsbellend | |
04/3/2021 09:42 | I am not sure what people expect from these events because they can’t tell you anything of importance that you don’t already know as that has to be released by RNS. You have to read between the lines because they can’t tell us what we want to know which is how much are Leap and EMMAC worth and when will the liquidity events take place. | 888icb | |
04/3/2021 09:17 | I hope your right. TBH. I thought it was a pretty amateur presentation. Nothing that we didn’t already know. Market seems to think the same too. Until we get a large event it will probably continue to drift. Leap , Emmac. Hopefully will boost this, but many here don’t have the patience. The BOD of companies often come out with these great expectations and exciting future, promises etc. As long as they keep it in that context they can say anything. | mellonsbellend | |
04/3/2021 09:08 | Ed was asked why he hadn’t bought any shares yet in FFWD.Ed did say they were in closed periods a lot and because he was so closely involved he was nearly always in possession of inside information . He is after all a Director of EMMAC where he is a larger shareholder than FFWD and he is now a Director of Leap Gaming both of which should be our big liquidity events this year. He therefore has a lot of knowledge which he can’t reveal but when he says they don’t intend to raise any more money this year because it will be provided by liquidity events and the Market cap will be over £100 million by the end of the year, he is sending a very clear message.. It is a very strong buy signal imho. | 888icb | |
03/3/2021 19:31 | Well they increased the market cap by over £4million over the last few months with their 2 placings A couple more of those and they will be close to the £50m they mention. LOL. | mellonsbellend | |
03/3/2021 19:27 | Rather disappointing after a good presentation which predicted a very promising year end Market cap and a very exciting next few months, to give up yesterday’s gain to finish 8.5% lower on volume of 2.8 million. However there is better news in Canada where rather unusually there is some volume at YOOM, currently Up 12.8% at 1.58 on volume of 449000. | 888icb | |
03/3/2021 12:25 | I have just listened to the presentation and Q&A which was interesting. Obviously they can’t reveal material information that hasn’t been released in an RNS so no further forward on the value of Leap and EMMAC other than being higher than in the last accounts. However an overall comment on Market cap gives us a big clue. £50m market cap first hurdle, really looking towards that triple digit market cap by the end of the year” That was a comment by Ed McDermott which will allow us to our own calculations knowing they should add up to £100 million. So 4x the current market cap by the end of the year,which would be a share price of circa 50p. I will be a very happy shareholder if they deliver that Share Price. | 888icb | |
03/3/2021 10:29 | Presentation on ffwd website if you want to read | jmid1000 | |
02/3/2021 16:05 | PRTG Available on DEGIRO now if anyone has that platform | jmid1000 | |
02/3/2021 14:29 | EMMAC LIFE SCIENCES GROUP AGREES SALE OF WELLNESS BRANDS TO YOOMA WELLNESS INC. EMMAC TO ACCELERATE GROWTH OF MEDICAL CANNABIS OPERATIONS 2 March 2021, London. EMMAC Life Sciences Group ("EMMAC" or the "Group" or the "Company"), Europe's largest independent cannabis company, is pleased to announce the strategic sale of its wellness brands to Yooma Wellness Inc. ("Yooma") (CSE: YOOM), an emerging marketer and distributor of cannabinoid and hemp-derived wellness products. Yooma will acquire the brands Blossom, MYO, Hello Joya and What the Hemp, after previously licensing the brands from EMMAC under the terms of an agreement announced on 20 January 2021. Antonio Costanzo, CEO of EMMAC, said: "EMMAC's strategic focus is to accelerate the growth of its medical cannabis and B2B wellness business operations. The strength of our vertically integrated business model and the investment made in our European facilities in the past year means that we have a compelling market advantage to deliver real revenue growth in these areas." International cannabis market research firm, Brightfield Group, project Europe's medical cannabis market to grow to over US$3.1 billion by 2025, with a 2020-2025 CAGR of 52%. Antonio Costanzo, CEO of EMMAC, continued: "As a result of this sale, Yooma has the opportunity to capitalise on the traction that EMMAC's wellness brands have made, particularly in the UK, and extend the distribution channels for these brands into China and further Asian markets." The total purchase price is approximately US$8.1 million, and will be payable as 7,459,981 shares of Yooma valued at their 5-day volume weighted average price of CA$1.384. Let’s see if this has any effect on YOOM shares today as we now hold them directly and indirectly via EMMAC. | 888icb | |
02/3/2021 14:25 | That's a good piece of business for both companies and Yooma should fly on that news in Canada today. Naughty market makers crashed the bid in order to trigger stops but buys are flooding in now. | the skipper | |
02/3/2021 14:13 | There is some news now about EMMAC and YOOM and up we go. | 888icb | |
02/3/2021 14:05 | Investor presentation tomorrow, leap or Emmac news my guess | jmid1000 | |
02/3/2021 13:12 | It feels as if news is coming now Up 8.2% a full 1p to 13.15 as the volume goes just over 1 million. If the volume picks up we could soon retest recent highs. News on Leap or EMMAC will see this move very quickly. | 888icb | |
02/3/2021 12:12 | Now Up 5.8% as bid moved from 12.3 to 12.7 with ask remaining at 13p despite last 7 trades being At 13p. Looking positive for this afternoon. | 888icb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions